Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iyad Alnahhas

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
BMC Research Notes|August 14, 2012
Undergraduate medical students' perceptions, attitudes, and competencies in evidence-based medicine (EBM), and their understanding of EBM reality in SyriaFares Alahdab, Belal Firwana, Rim Hasan, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 31, 2024
Body mass index as a prognostic indicator of overall survival in glioblastoma: A systematic review and meta analysisPreston Carey, Christopher Gardner, Adam Uppendahl, et al.
Neuro-Oncology Advances|March 6, 2026
Metformin exposure after glioblastoma diagnosis and mortality: A large population-based studyVittorio Maio, Roshani Shah, Manisha Lin, et al.
Chinese Clinical Oncology|July 7, 2023
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trialLouis Cappelli, Mehak Majid Khan, Allison Kayne, et al.
Neuro-Oncology Advances|July 14, 2021
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysisIyad Alnahhas, Mouaz Alsawas, Appaji Rayi, et al.
Neuro-Oncology Advances|November 5, 2020
Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysisIyad Alnahhas, Mouaz Alsawas, Appaji Rayi, et al.
Cancers|February 6, 2019
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A ReviewDenise Fabian, Maria Del Pilar Guillermo Prieto Eibl, Iyad Alnahhas, et al.
Neuro-Oncology Advances|June 27, 2025
Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progressionLouis Cappelli, Allison Kayne, Jennifer Newman, et al.
Neuro-Oncology Advances|May 14, 2026
MGMTai: O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) methylation prediction in isocitrate dehydrogenase (<i>IDH</i>)-wild type glioblastoma to direct temozolomide therapyPatricia Pittman, Chen Sun, Timothy Samec, et al.
Journal of Neuro-Oncology|November 10, 2022
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot studyAyesha S Ali, Joseph Lombardo, Muneeb Z Niazi, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
BMC Research Notes|August 14, 2012
Undergraduate medical students' perceptions, attitudes, and competencies in evidence-based medicine (EBM), and their understanding of EBM reality in SyriaFares Alahdab, Belal Firwana, Rim Hasan, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 31, 2024
Body mass index as a prognostic indicator of overall survival in glioblastoma: A systematic review and meta analysisPreston Carey, Christopher Gardner, Adam Uppendahl, et al.
Neuro-Oncology Advances|March 6, 2026
Metformin exposure after glioblastoma diagnosis and mortality: A large population-based studyVittorio Maio, Roshani Shah, Manisha Lin, et al.
Chinese Clinical Oncology|July 7, 2023
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trialLouis Cappelli, Mehak Majid Khan, Allison Kayne, et al.
Neuro-Oncology Advances|July 14, 2021
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysisIyad Alnahhas, Mouaz Alsawas, Appaji Rayi, et al.
Neuro-Oncology Advances|November 5, 2020
Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysisIyad Alnahhas, Mouaz Alsawas, Appaji Rayi, et al.
Cancers|February 6, 2019
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A ReviewDenise Fabian, Maria Del Pilar Guillermo Prieto Eibl, Iyad Alnahhas, et al.
Neuro-Oncology Advances|June 27, 2025
Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progressionLouis Cappelli, Allison Kayne, Jennifer Newman, et al.
Neuro-Oncology Advances|May 14, 2026
MGMTai: O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) methylation prediction in isocitrate dehydrogenase (<i>IDH</i>)-wild type glioblastoma to direct temozolomide therapyPatricia Pittman, Chen Sun, Timothy Samec, et al.
Journal of Neuro-Oncology|November 10, 2022
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot studyAyesha S Ali, Joseph Lombardo, Muneeb Z Niazi, et al.
Pageof 3